Biocoat Launches Coating Equipment Business Unit; Completes Full-Service Hydrophilic Coating Offering

Biocoat Inc. announced its expansion into the design, development and delivery of hydrophilic dip coating equipment.  Biocoat’s new equipment line is called EMERSE and offers companies who require an in-house dip coating system to coat their medical devices and complete the production process.

The addition of coating equipment now positions Biocoat as one of the only companies that can offer a complete, full-service solution for medical devices that require a hydrophilic coating. The EMERSE hydrophilic dip coating system is specifically designed and manufactured to meet the rigorous requirements that are encountered when coating products in the medical device, pharmaceutical, biotechnology and life science industries. Biocoat’s coating systems will be available in either Thermal heat or Ultraviolet (UV) cure systems and is available in two models, the semi-automated Compact system, that offers an annual production of ~25,000 units per year per shift and the One Touch automated system that can coat ~75,000-100,000 units per year per shift.

“The addition of coating equipment fulfills our strategic vision of making Biocoat the premier full-service coatings company to partner with for medical device companies.” said Jim Moran, President, and CEO, Biocoat. “Our coating systems will be automated and fully compatible for use on either our industry leading HYDAK® coatings or any other coatings in the market. Our aim is to work closely with our customers to provide the highest level of service available, while ensuring that we deliver the equipment on-time and on-budget, every time.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.